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Review Article: Modern Trends in Imaging X
Spectral imaging in preclinical research
and clinical pathology
Richard Levensona,∗, Joseph Beechemb and George McNamarac
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bGenetic Systems, Life Technologies, Foster City, CA, USA
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Abstract. Spectral imaging methods are attracting increased interest from researchers and practitioners in basic science, pre-
clinical and clinical arenas. A combination of better labeling reagents and better optics creates opportunities to detect and measure
multiple parameters at the molecular and cellular level. These tools can provide valuable insights into the basic mechanisms
of life, and yield diagnostic and prognostic information for clinical applications. There are many multispectral technologies
available, each with its own advantages and limitations. This chapter will present an overview of the rationale for spectral
imaging, and discuss the hardware, software and sample labeling strategies that can optimize its usefulness in clinical settings.
Keywords: Image analysis, immunofluorescence, immunohistochemistry, machine-vision, multispectral imaging, oncology,
pathology, personalized medicine, segmentation
1. Opportunities in pre-clinical and clinical
tissue analysis
The tasks facing pathologists have multiplied in
recent years. Diagnosis (their traditional deliverable)
has mainly relied on principles derived from correla-
tive morphology; now, however, pathologists are asked
to go beyond assigning labels to lesions, and to provide
refined prognosis, therapeutic guidance and even treat-
ment monitoring via a series of biopsies or fine-needle
aspirations of unresected primaries or metastases. In
the realm of translational research, pathology is called
upon to validate other forms of imaging and detec-
tion, some of these molecularly based, as well as to
guide drug development from early pre-clinical to late,
post-approval clinical stages [1]. Many of these new
roles depend on detecting the abundance and possi-
bly the activation state of an increasing number of
molecules-of-interest present in tissue samples. If such
molecules can be correlated with appropriate drug
∗Corresponding author: Richard Levenson, Pathology and Labo-
ratory Medicine, University of California Davis, Sacramento, CA,
USA. E-mail: Levenson@ucdavis.edu.
choice and patient outcome, and can navigate through
the FDA (or equivalent) approval process, they become
so-called “companion diagnostics” and their assay may
be mandated as part of a therapeutic regimen espe-
cially as they tie in with individualized patient profiling
and drug selection [2]. These new tasks may out-
strip the capability of conventional pathology reagents
and imaging tools, especially, as is increasingly the
case, when the amount of available tissue is limiting.
Fortunately, relatively new reagents, methods and soft-
ware approaches have been developed that can help
address these challenges. (Disclaimer: due to space-
and author-limitations, related approaches using FRET
(Fo¨rster resonance energy transfer) or FLIM (fluo-
rescence lifetime imaging microscopy) will not be
discussed here).
New molecular targets for research, diagnosis or
screening (often called “biomarkers”) are being iden-
tified, seemingly daily, and while some of these are
detectable in body fluids (or even in exhaled breath),
many of them are most informative when visualized in
largely intact cells and tissue. Tissue-based detection
of molecular events takes advantage of accumulated
experience developed through decades of examining
2210-7177/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved
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samples stained with standard histology dyes [3, 4]
— consequently, a molecular phenotype can be inter-
preted with the help of a rich biological context.
Compatible, histology-based imaging methods include
immunofluorescence (IF) and immunohistochemistry
(IHC) [5]; their development during mid-to-late-20th
century ushered in the era of true molecular pathol-
ogy. Antibody-based methods can go beyond antigen
localization to provide information on protein post-
translational modifications such as phosphorylation
and de-phosphorylation. Such alterations are known to
play important roles in signaling pathways [6–14] and
function in a complex web of positive- and negative-
feedback [8, 9, 11, 12, 14–17]. It is probable that similar
relevant molecular assays may eventually become
part of the practice of clinical anatomic pathology,
but the current lack of consensus on which assays
to use confirms the complexity and heterogeneity of
cancer progression and underscores a need for new
approaches [18–23], perhaps focusing on so-called
driver molecules [24]. On the nucleic acid side, con-
ventional in-situ hybridization techniques targeting
DNA and mRNA have been recently been extended
to include non-coding RNAs such as miRNAs and
lincRNAs [25–27].
2. Why use microscope-based imaging for
molecular phenotyping?
As appreciation of the complexity of disease-
relevant molecular interactions has deepened, so has
the need for techniques that can look at more than
one analyte at a time. Such molecular phenotyping
can be image-based, or it can rely on techniques that
extract molecules from their native location before
assaying them. Imaging tissue, with IHC or IF, for
example, can be slow, complex and subject to a host
of confounding problems with tissue preparation and
molecular detection, and are limited to the number
of molecules that can be simultaneously detected.
In contrast, other extremely powerful and exciting
multiplexed molecular analysis methods, which now
include proteomic techniques and targeted or deep
whole genome sequencing, can survey hundreds to
millions of molecular events in parallel from a sin-
gle specimen. There is no doubt that such approaches
will have unforeseeable and profound impacts on biol-
ogy and medicine, but because these techniques are
largely not informed by spatial context, major insights
may be lost and quality assurance is made more diffi-
cult. One problem is posed by sample heterogeneity. If
the detection systems do not have good dynamic range,
molecular phenotypes representing the bulk population
can swamp out real but small signals from small cell
populations [28, 29]. These minority populations can
be of potentially greatest interest, as in the case of can-
cer stem cells thought to represent a small but critical
part of a tumor ecosystem. Secondly, it is not always
the case that the signal seen actually came from the
cells intended to be the investigation target. For exam-
ple, some samples of tissue submitted for genomic
analysis may have actually little or no tumor present,
or the tumor cells may be so diluted by host-derived
cells that the measured phenotype becomes difficult
to interpret. Some of these problems can be addressed
via careful sample preparation, including laser capture
microdissection [30, 31].
Microscopic-based imaging, on the other hand,
while not achieving the depth of molecular coverage
that the ensemble techniques can generate, never-
theless can provide unique and/or complementary
information. First of all, the fact that single cells can
be visualized means that even rare cell populations
can be studied without their signals being swamped by
those of the majority. Individual Hodgkin’s cells can
be detected and studied even when surrounded by a sea
of reactive immune cells [32]. A related advantage is
that all components of an important and complicated
microenvironment can be examined simultaneously,
providing insight into biological cross-talk present at
the tumor-host interface [33]. Also, the image itself
provides validation that the tissues being examined
are in fact the intended ones. Perhaps more impor-
tantly, image-based techniques can yield molecular
information with spatial precision that spans many
orders of magnitude, from the subcellular level (even
to single-nanometer scale) all the way up to whole
organs. Moreover, such spatial precision gains extra
value when several molecules (or cell types) can be
detected simultaneously and their location with respect
to one another evaluated.
To the extent that antibody panels [34, 35] are
usually assayed using many serial sections can be mul-
tiplexed instead onto a single slide, there could be
benefits realized in workflow, cost and case-review
effort. Advantages of multiplexing are even greater
when only limited sample is available. Not only can
more information be obtained from less tissue, but cor-
respondingly more tissue is then available for other
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molecular tests. Unfortunately, recent changes in reim-
bursement policies in the US that discourage the use
of multiple stains on single slides may strongly work
against this trend, at least in the short run.
3. Bright field vs. fluorescence (or IHC vs. IF)
There is an on-going debate as to the relative mer-
its of bright field vs. fluorescence when it comes
to performing molecular detection in tissue. Pathol-
ogy still relies almost exclusively on the traditional
microscope, with light projected through the sample
towards the eyepieces or camera (bright field mode).
Contrast is generated by absorption and scattering, typ-
ically by organic stains such as hematoxylin and eosin,
and/or by chromogens (colored labels) deposited at or
near molecular targets. Fluorescence, which uses light
emission, rather than absorption, is by contrast, the
dominant technique in basic research settings, but is
rarely found in the clinic—with the exception of some
relatively low-volume skin and renal immunopathol-
ogy applications and fluorescence in-situ hybridization
(FISH) assays for HER2 amplification. The situation
may eventually change because fluorescence-based
techniques have the potential for increased sensi-
tivity, improved dynamic range, suitability for high
levels of multiplexing even when signals are over-
lapped, no requirement for enzymatic amplification
(and therefore, improved linearity) and potential for
single-cocktail labeling approaches [36].
New labeling reagents have increased the possi-
ble utility and clinical acceptability of fluorescence
techniques. The advent of quantum dots (QDs),
semi-conductor-based fluorescent nanoparticles, for
example, was expected to boost clinical utilization of
fluorescence due to these agents’ relative resistance
to photobleaching and reasonable stability in stained
samples; their simplified optical requirements (sin-
gle excitation wavelength), and reports of successful
tissue-based multiplexing [37–39] led to early enthu-
siasm. However, quantum-dot-based labels have not
yet achieved widespread adoption, in part due to their
own properties as well as to other challenges that
fluorescence-based methods face in general [38]. One
of these is interference from various sources of aut-
ofluorescence, especially common with formalin-fixed
tissue samples [40–45]. Additional hurdles include the
requirement for complex and expensive microscopes,
and interference with typical pathology workflow.
Equally importantly, fluorescently stained specimens
do not resemble familiar bright field samples, and
because they frequently do not include a non-nuclear
counterstain (essentially, an eosin equivalent), it can
be very hard to see beyond the possibly sparse labels
to appreciate what the sample actually looks like.
The much more popular bright-field chromogenic
(colored) stains that only absorb rather than emit light
have their own set of advantages and drawbacks. Most
notably, especially when counterstained, the samples
appear familiar, and provide good spatial context for
the molecular signals. The stains are relatively stable
and do not require special storage or viewing stations.
It is a major challenge, however, to achieve repro-
ducible staining intensities with typical enzymatically
enhanced chromogen deposition (a non-linear process
sensitive to reaction conditions), and comparisons on
inter-institutional staining and interpretation of IHC
samples have often demonstrated low agreement lev-
els [46], although reasons for irreproducibility involve
far more than just the chromogen deposition step. On
the plus side, the optical measurement of the absorb-
ing molecules can be done in optical-density mode,
which should yield instrument-independent values.
This property can facilitate robust inter-institutional
comparisons (assuming the sample preparation and
staining methodologies are well controlled [47]). A
major disadvantage of bright field molecular imaging
is that, without some form of enhanced spectral dis-
crimination, it can be difficult to impossible to resolve
multiple overlapping colors and obtain even qualita-
tive data from multiplexed chromogenically stained
samples.
4. Standard microscopy and its discontents
Many pathologists may feel that additional tools
beyond just a microscope, their own eyes, and possibly
a digital camera, are not actually needed, and they
are concerned that novel, potentially expensive and
intrusive technology may not be worth its cost in either
money or time. But as the number of simultaneous
molecular targets examined goes up, the limitations
of standard imaging methods become increasingly
apparent.
The spectral resolution of the human retina (and
RGB cameras) is limited to 3 major and overlapping
spectral ranges (red, green, blue). The sensations of
colors arise from differential stimulation of these 3
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Wavelength Wavelength
Fig. 1. Color and spectral content are not synonymous.
receptors, and it should not come as a surprise that there
might be more than one way to stimulate the receptors
to equivalent activation levels. For example, the sensa-
tion, “yellow,” arises when the red and green receptors
receive equal stimulation. This can be accomplished
by a near-infinite set of combinations of other wave-
lengths in the green-red range, a phenomenon known
as metamerism [48]. Obviously, this redundancy only
deepens when more than two signals spatially overlap,
and is true in both fluorescence (additive) and bright
field (subtractive) color environments.
Conventional fluorescence imaging based on
monochrome cameras and appropriate narrow-band
filters would have no problems distinguishing a true
yellow emitter from red-plus-green signals; never-
theless, this optical set-up is still challenged by the
broad emission spectra (and long red tails) of most
organic fluorochromes, leading to overlap or crosstalk
between channels. It is difficult to design a set of filters
with acceptable light-throughput that can transmit light
coming from just one fluorescent species while com-
pletely blocking that of another. While good separation
can be achieved using multiple filter sets in standard
fluorescence microscopes (up to 6 can be installed in
typical research system), and even greater flexibility
is available if filter wheels on both the excitation and
emission paths are used [49], such flexibility involves
increased cost and complexity.
Hard-to-resolve mixtures of fluorescent signals in
many or most separate channels can be inevitable
when autofluorescence is present. Autofluorescence
is the often-unwanted spontaneous fluorescence emis-
sion of the cells or tissues being imaged not arising
from the exogenous dyes used for labeling [44, 45].
Autofluorescence is typically broad, extending a
hundred nanometers or more, and can be intense,
especially with plants, insects, worms, fish, neurons
and formalin-fixed tissues in general. It results in a
greenish-yellow haze with conventional red or green
filter sets and can decrease contrast or overwhelm
weak signals entirely. While a number of approaches
to getting rid of autofluorescence chemically have
been developed [42–45, 50], they may not be partic-
ularly effective or generally applicable. The intensity
of autofluorescence drops dramatically when the sam-
ple is excited in the red and near-infrared regions, a
phenomenon that has motivated the development of
fluorochromes emitting in the far-red. However, the
availability of NIR dyes does not solve the problem
of spectral overlap and autofluorescence in the much
more populated visible range.
5. Spectral imaging can help
Spectral imaging (also referred to as multispec-
tral or hyperspectral imaging) is a technique that has
been used in research and development in the bio-
sciences since the 1990 s, and is finally gaining traction
as the hardware and software have improved, addi-
tional application needs are emerging, and convenient
multispectral reagents, including quantum dots and
appropriately labeled primary antibodies, are becom-
ing available. Some of the hardware and software
approaches will be outlined below. Simply put, the
technique provides a spectrum (with variable spec-
tral resolution) at every pixel of an image. Analysis is
based on well-validated standard spectroscopic algo-
rithms used for decades for detecting, “unmixing” and
quantitating components in mixtures; spectral imag-
ing software essentially adapts those approaches to
provide pixel-by-pixel quantitative data. What spectral
imaging offers over conventional methods is improved
detection, validation, separation, and quantitation [40,
51, 52].
5.1. Detection
Autofluorescence, if sufficiently bright, can com-
pletely mask the presence of desired signals.
Somewhat paradoxically, spectral imaging, although
less light-efficient overall than typical microscopy
techniques, can increase sensitivity due to the increased
information content of the captured signals, and can
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Fig. 2. Removal of autofluorescence reveals an otherwise unde-
tectable YFP+ transfected cell.
detect otherwise invisible, or rather, indistinguishable,
targets. An example is given in Fig. 2, which shows
a number of cells with autofluorescence, only one
of which was expressing yellow fluorescent protein
(YFP). Using the spectrum of the autofluorescence and
YFP spectrum alone, the image can be separated to
reveal the autofluorescence signals (all cells equally
bright, predominantly nuclear, low contrast) and the
single YFP-positive cell, whose signals are predomi-
nantly cytoplasmic. In this case, the YFP signal in the
positive cell was present at only about one-tenth the
level of the autofluorescence.
5.2. Validation (or identification)
By having the spectral characteristics associated
with each channel, a user can confirm, for example,
that the green signals in their specimen that look so
promising are indeed generated by a fluorescent label,
such as Alexa Fluor 488 or green fluorescent protein,
for example, rather than being simply brightly autoflu-
orescent tissue elements. The latter may often appear
greenish (especially through a narrow-band emission
filter), but will almost certainly have a detectable opti-
cal spectrum easily distinguished from that of the
fluorescent label (see spectra in Fig. 2). Shown in
Fig. 3, a formalin-fixed, paraffin-embedded section of
highly autofluorescent prostate tissue was stained for
Fig. 3. Removal of autofluorescence reveals dim signals.
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Fig. 4. Effects of nucleic acid binding on TOTO-1 spectra—detection of RNA-rich nuclear regions.
PSMA expression using a green quantum-dot-labeled
antibody. The truly bright signals in the color image
(top left) were due entirely to autofluorescence. Even
a narrow bandpass filter centered on the peak, 535-nm
emission of the quantum dot label (upper right panel)
did not reveal the luminal distribution location of the
PSMA molecules, which required spectral unmixing
to demonstrate.
Spectra can reveal environmental effects on single
dye emissions, as illustrated in Fig. 4, which shows
how spectral imaging can be used in an exploratory
mode. A cell was stained using the nucleic acid dye,
TOTO-1, spectrally imaged on a confocal instrument,
and spectra extracted from the nucleus (presumably
reflecting largely DNA-binding events) and the cyto-
plasm (RNA and possibly minor contributions from
mitochondrial DNA). Using these spectra, the image
was unmixed (although classification would have given
the same results) to delineate RNA-rich regions of the
nucleus. The spectra taken from the cell were com-
pared to spectra taken in solution when TOTO-1 was
complexed with purified RNA and DNA; the similari-
ties are evident.
Alternatively, autofluorescence arising from “inter-
esting” endogenous molecules may also carry useful
spectroscopic information. Autofluorescence spectra
of, for example, NAD(P)H [53], flavins and flavopro-
teins [54], advanced glycation end-products (AGEs)
[55], collagen and elastin [56], lipofuscins [57] and
protoporphyrin IX [58] can provide insights into nor-
mal and pathological specimens [59, 60].
5.3. Separation (also known as multiplexing)
Being able to view multiple (molecular) signals
simultaneously is one of the main attractions of
spectral imaging. There are two main approaches.
One is signal separation of multiple labels through
spectral unmixing algorithms. The second may use
unmixing as a first stage, but relies on bar-coding
techniques to increase the number of distinguishable
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entities, potentially by orders of magnitude. Both will
be discussed in greater depth below.
5.4. Quantitation and analysis
Sensitive detection and accurate signal unmixing are
prerequisites for valid quantitation of signal intensities
and other objective measurements. If signal loca-
tion and intensity cannot be determined precisely, all
further computations may be suspect. Spectral imaging
can convert semi-quantitative to quantitative assays,
while improving lower limits of sensitivity (as shown
in Figs. 2 and 3). It is consequently very important that
spectral segmentation and/or unmixing be performed
accurately, since errors at those steps will propagate;
as with every complicated technique, the methods and
algorithms must be validated and appropriate controls
included [47].
Images with the location and intensities of the
unmixed signals may be all that is necessary, since
pictures may convey all the insights required. On the
other hand, quantitation typically requires some spa-
tial manipulations (identification of regions of interest,
segmentation of nuclei, identification of subcellular
compartments, etc.) and these may benefit from man-
ual or automated image analysis tools, discussion of
which is beyond the scope of this chapter. This is a
rapidly evolving field; the new Journal of Pathology
Informatics is a good source for recent publications.
6. Some spectral imaging hardware
approaches
A tribute to human ingenuity is the fact that there
are at least 10 or so quite different technology vari-
ants of spectral imaging, including filtered cameras
(with a number of flavors), whiskbroom and pushb-
room scanners, such as the Specim or PARISS systems
[61, 62], multispectral laser confocal systems [63, 64],
Fourier transform imaging spectrometers [65], com-
puted tomography imaging spectrometers (CTIS) [66],
image replicating imaging spectrometers (IRIS) [67,
68], coded aperture snapshot spectral imagers (CASSI)
[69, 70], and snapshot spectral image slicing [71]—and
that only covers emission-side spectroscopy [72–74].
Illumination light can also be be spectrally modulated
to provide similar information [Frank, 2007 #7670,
75].
These methodologies capture spatial and spectral
information using very different imaging geometries.
Spatially, images can be acquired one point at a time
(e.g., a confocal laser scanner), one line at a time, or a
full frame at a time. The first case typically requires a
laser spot scanning over a sample, the second requires
either the sample or the optics to move, and the third
typically requires no movement of either sample or
imaging optics.
Spectrally, images can be acquired one wavelength
at a time (“band-sequential”), or many wavelengths
simultaneously—typically by diffracting the light so
that the spectral information is dispersed along a col-
lector, such as a multi-anode PMT or CCD. Airborne
remote-sensing imaging systems typically utilize a
line-scan approach, in which linear slices of the field
are spectrally dispersed onto a 2-dimensional digital
sensing array (a CCD or other device for detection
outside of the visible region). This geometry has been
adapted for use on the microscope by incorporat-
ing a scanning stage to move the slide underneath
the detector (e.g., Specim or PARISS). An alterna-
tive way of collecting all wavelengths simultaneously
involves Sagnac Fourier-transform interferometry
[76], although this approach still requires the cap-
ture of multiple full-frame images and subsequent
computation.
Finally, some approaches allow the collection of
both spectral and spatial information simultaneously,
and in a single acquisition (“snapshot”). These include
computed tomographic imaging spectroscopy (CTIS)
[66], or spectral image slicing [71], or simply arranging
multiple spectrally filtered images onto single or
multiple camera sensors, as in the Quad View prod-
uct from Photometrics, or an intriguing variant that
uses RGB sensors and custom color bandpasses
[77].
The imaging slicing spectrometer has recently been
commercialized by Rebellion Photonics, and can gen-
erate up to a 500 × 500-pixel image in as many as 200
spectral bands in a single snapshot with good light-
capture efficiency. Frame-rates up to 100 frames per
second are offered, along with real-time video-rate
spectral unmixing. While simultaneously achieving
high temporal, spectral and spatial resolution is a
formidable challenge, it appears that this goal can be
achieved. Nevertheless, at present, the most commonly
used spectral imaging techniques are those found in
confocal-based systems, the Sagnac Fourier-transform
interferometer (ASI), and a variety of band-sequential
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approaches such as those commercially available from
CRI (now PerkinElmer) and Gooch & Housego.
Regardless of the hardware technology used, a
spectral imager delivers three-dimensioned image sets
(x, y, and wavelength intensity) that contain spectral
information at every pixel. While “true” spectral
imaging can deliver spectra containing hundreds or
even thousands of spectrally distinct intensities at
each pixel, such imaging spectroscopy is generally
of less practical use than it might seem, depend-
ing on the task at hand. Capturing a subset of the
available spectral information is usually sufficient
and preferred—superfluous spectral data may simply
increase statistical noise, processing time and storage
requirements. Development of strategies for minimiz-
ing the amount of data collected while maximizing
system performance remains an area of active research
[78–80].
7. More on emission side band-sequential
imaging
Band-sequential spectral imaging is one of the more
straightforward techniques, since in its simplest form
it can be accomplished simply by having a filter wheel
containing multiple transmission filters (up to 20 in
some systems) located in the optical train in front
of the camera. The system takes a series of images
while switching filters to create a spectral data stack.
Large fields of view and/or high pixel resolution can
be achieved with this approach. Flexibility can be
achieved by having a many-position filter wheel, or the
ability to swap in and out filters with different bandpass
properties.
A particular advantage of this kind of imager is that
the number of spectral bands acquired is completely
up to the user, as opposed to techniques that collect
continuous spectra, such as diffraction grating-based
methods. Also, and importantly, dynamic range can be
preserved, since different exposures can be employed
at different wavelengths. This is helpful if, for exam-
ple, a DAPI nuclear stain in the blue is extremely
bright compared to a low-intensity fluorescent label
in the green or red regions. Having the ability to take
a very short exposure at 420 nm (blue) and a long
exposure at 680 nm (red) allows both signals to be
acquired with good signal-to-noise and without cam-
era saturation. Disadvantages of filter-wheel methods
include vibration, possible image shifts as different
filters are rotated into the field of view, and bulky
form-factors. Relatively slow switching speeds of the
mechanical device can also dominate acquisition times
and make it difficult to capture complete spectral stacks
quickly enough to be practical for imaging transient
phenomena and/or moving specimens. A variant of the
filter-based approach synchronizes a rapidly and con-
tinuously spinning filter disk with a high-speed camera,
allowing the capture of several multispectral images
per second, as is possible with the SpectroCam from
Ocean Thin Films.
Electronically tunable filters represent a promising
alternative to mechanical filter wheels for a number of
reasons. For one thing, there are no essential moving
parts, and thus no noise or vibration is generated during
wavelength switching. Secondly, the bandpasses are
stable, compared to at least older-generation glass fil-
ters that could age or delaminate. Electronic filters can
be randomly tuned, so that bands can be obtained in any
order. This can be an advantage if some dyes need to be
imaged first during data collection due to photostabil-
ity issues. Also, with some technologies, transmission
properties can be electronically altered to give control
over the bandwidths and thus manipulate the trade-off
between spectral resolution (the narrower the band-
width, the higher the resolution) and light-capture
efficiency (optimized with a large bandwidths). Dis-
advantages of most tunable filters include the fact that
overall light throughput is less than that of traditional
interference filters, by at least a factor of two (because
typical tunable filters are polarization-sensitive, and,
compared to interference filters, electronic filters usu-
ally have reduced out-of-band light rejection.
Two major tunable filter technologies are avail-
able: liquid crystal tunable filters (LCTFs) [81] and
acousto-optical tunable filters (AOTFs) [16, 82].
Both of these have been incorporated into complete
imaging systems ready for use on conventional micro-
scopes via standard C-mounts, and are accompanied
by capable software suites. Both technologies can
acquire spectral datasets over similar wavelength
ranges, and in both cases, separate filter models are
required to address visible vs. near-infrared vs. mid-IR
regions. In typical use, one would tune the filter to a
desired wavelength, take a monochrome image, step
the filter (often with a 10- or 20-nm interval), take
another image, and so on. This process can be fully
automated. The images are assembled into a spectral
stack in the computer’s memory and are available for
immediate analysis, unlike other systems that may
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require computationally intense iterative procedures
to estimate spectral content. Well-designed tunable
filters can offer diffraction-limited resolution, or even
beyond; one recent reference described using surface
plasmon particles imaged in dark field with 1-nm
spectral resolution and 1.2 nm spatial resolution [83].
The time to acquire a complete stack depends
strongly on a number of factors, most significantly on
the number of wavelengths imaged, exposure times,
filter-switching time, and camera-read-out rates. One
major distinction between LCTF- and AOTF-based
systems is filter-tuning speed. An LCTF typically can
tune from one wavelength band to another in 50 to 75
milliseconds, whereas an AOTF can tune from band
to band in about 50 microseconds. When coupled with
a fast camera, the AOTF’s tuning speed opens up the
possibility of near-real-time (i.e., video-rate) imaging
in which complete spectral cubes (with a relatively
small number of wavelengths) can be acquired, pro-
cessed and displayed without significant visual lag.
This of course requires that exposure times be short,
but that can be the case in bright field imaging of chro-
mogenically labeled specimens or with particularly
bright fluorescent samples.
Another venerable tunable filter design, originated
by C. Fabry and A. Perot back in 1899, is being revived
by VTT (www.vtt.fi) with new optical coatings and
inexpensive control hardware. With sub-millisecond
tuning speed, up to 80% optical throughput and
price points in the hundreds to low-thousands of dol-
lars/euros per filter, Fabry-Perot technology may find
its way into reasonably priced spectral imaging sys-
tems in the future.
8. Excitation- or illumination-side spectral
Imaging
Wavelength control of fluorescence excitation
sources or of bright field illumination offers some
advantages over “camera-side” spectral filtering. For
one thing, it is only the illumination path that is mod-
ulated, which leaves the optical path from sample to
camera unaffected by additional optical elements such
as tunable filters that can steal light and potentially
affect image quality. Secondly, some illumination-side
spectral sources can be tuned very rapidly, allowing
for high-speed imaging. Finally, tuning the excitation
source while capturing broadband emissions is essen-
tially performing fluorescence excitation spectroscopy
[84]; the resulting data can be used equivalently by
spectral unmixing algorithms [85, 86].
Fluorescence illumination can also benefit signifi-
cantly by being able to select and apply one or more
illumination wavelengths perfectly matched to absorp-
tion maxima of different dyes. For wide-field fluo-
rescence microscopy, there are a number of potential
technologies to choose from. Monochromator-based
light sources such as the Polychrome (Till Photonics),
MEMS-based tunable sources such as those from One-
Light or Gooch & Housego, and multi-LED solid-state
light sources (e.g., Spectral X Light Engine, Lumen-
cor; InsightSSI, Applied Precision; Colibri, Zeiss;
Photofluor, 89 North; X-Cite LED1, Lumen Dynam-
ics) enable rapid wavelength switching and selectable
bandpasses. The same hardware facilitates rapid exci-
tation switching to image eGFP, mCherry and other
fluorescent proteins, including ratiometric fluorescent
protein calcium sensors, pH, cAMP, and others.
Modern confocal microscopes are generally
equipped with one or more lasers, with typical output
being 405, 458, 476, 488, 514, 561, 592, and 633 nm.
Thanks to the broadness of the excitation spectra
of most fluorescent organic dyes and fluorescent
proteins, most confocal microscopes have not needed
excitation spectral tuning beyond that provided by
multiple lasers to achieve useful separation of each
fluorophore. The addition of tunable Ti:Sapphire
lasers for generation of multiphoton fluorescence
and second-harmonic and third-harmonic signals has
added new capabilities to microscope imaging, and
provides for additional excitation flexibility. Going
further, some confocal microscopes are now equipped
with supercontinuum white light lasers. Combined
with wavelength selection (e.g., via AOTF or AOM
control), this type of laser can deliver rapidly tunable
fluorescence excitation at any wavelength over a wide
spectral range.
9. Conventional filter cubes—still needed for
multispectral imaging?
Fluorescence imaging requires that the very bright
excitation light be excluded from the emission light
path to avoid overpowering much weaker fluores-
cent emitted signals. Typically this is accomplished
with sets of excitation and emission filters paired
with appropriate dichroic mirrors that together block
residual excitation light by as much as a million-
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Fig. 5. Five quantum dots plus DAPI spectrally imaged, unmixed and displayed. The DAPI spectrum is shown, but the DAPI signal is not
included in the composite image.
fold. Unfortunately, the tunable elements in many
multispectral imaging systems only block out-of-band
light by a factor of about 10,000-to-1, not sufficient
to clean up all the unwanted excitation light. Con-
sequently, a conventional interference filter is still
required in front of the tunable optics to block exci-
tation wavelengths. In any case, this is required for
eye-safety with standard microscope configurations:
most spectral imaging devices are connected to the
microscope via a standard C-mount, and are thus
“downstream” of the eyepieces. Without a standard
emission filter in place to block excitation light, dan-
gerous levels would be transmitted through the oculars
and into the eyes of the microscope operator.
The advent of quantum dots reagents [38, 87–89]
promised to simplify spectral imaging drastically, since
quantum dots, regardless of emitted color, can be
excited by wavelengths shorter than their emission
peak. Thus, a single standard DAPI cube, for exam-
ple, with a 500-nm longpass emission is able to excite
and transmit all QD emitters from green to far-red with
reasonable efficiency, as shown in Fig. 5.
Encouragingly, recent and intriguing developments
in optical design suggest that full-range emission and
excitation spectroscopy can be achieved without stan-
dard emission filters at all [90]—using polarization and
structured illumination to reject out-of-band excitation
light. These authors suggest that multispectral emis-
sion discrimination could be employed as a blocking
strategy as well, and this was demonstrated by Gao
et al. [91]. In the latter case, the authors suggest that a
3-fold improvement in signal-to-noise is achievable.
10. Other considerations
Other considerations for acquisition strategy include
the selection of spectral range, spectral bandwidth
(trading off spectral resolution with photon capture
efficiency) and the total number of images to be
acquired [92]. Clearly, one would like to use as small
a spectral range and as few total image acquisitions as
possible in order to cut down on imaging time, pho-
tobleaching and file size. In practice, however, when
users start to use some commercial multispectral sys-
tems they may not stray from the default (full-range)
settings for typical acquisitions, resulting in spec-
tral datasets consisting of full-frame, full-resolution
images from ∼400 to ∼700 nm with spectral steps
every 10 or 20 nm, which is almost always surplus
to requirement. The resulting bulky files and slower
acquisition and analysis performance may induce new
users to revert to imaging with more familiar, if less
capable, conventional systems.
On the other hand, if the high-resolution spectral
data is used initially to explore the spectral properties
of specimens and labels, the information obtained can
be used to optimize acquisition parameters for
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multispectral or even conventional imaging
approaches [93].
11. Image and spectral visualization,
classification and unmixing
After a spectral data set is acquired, it is presented
to the user, typically by mapping the series of spec-
tral planes into a standard color (RGB) image that has
nevertheless an optical spectrum associated with every
pixel. The user can then use this image to help guide
further analysis. Using the display tools in typical anal-
ysis software, one can “mouse” over the image and see
a live spectrum associated with each pixel presented in
another region of the screen. Mapping spectral infor-
mation into an RGB image can be adjusted by changing
which spectral ranges get combined to form the red,
green and blue planes. Thus, fluorescent signals in the
invisible, near-infrared region can be mapped into the
red region, red-region intensities mapped to green, and
so on.
Spectral image data sets can be remarkably rich in
information and require appropriate (ideally, easy-to-
use) techniques for analysis. The simplest tools are
also some of the most useful, namely, straightforward
spectroscopy, classification and unmixing. Supervised
use of these tools requires the user to interact with a
spectral library module that permits assignment of dif-
ferent spectra, typically via a series of colored (and
name-able) buttons. By clicking on a colored box and
then clicking or clicking-and-dragging in the display
window over user-specified pixels particular spectral
classes can be assembled, and their spectra shown in
the spectrum display window. The spectral features
usually are created by averaging the spectra from each
selected pixel or area into a single, average spectrum,
although some sophisticated analysis algorithms may
utilize second- or higher order statistics [94]. The spec-
tral library and display tools allow the user to directly
compare spectra of different regions or objects and
to download the spectra for further analysis. Spectra
can also be stored and recalled for use in subsequent
imaging sessions.
11.1. Spectroscopy
Fluorescent molecules can be sensitive to their envi-
ronment, shifting excitation or emission properties.
Fig. 6. Classification vs. unmixing.
This can either be a nuisance or a benefit, depending on
the application. Consequently, one of the most useful
and straightforward applications of spectral imaging is
the measurement of the emission spectra of dyes in situ,
rather than “in cuvetto,” allowing for optimization of
imaging parameters and increased understanding of the
cellular milieu (Fig. 4). Other uses for spectroscopic-
quality imaging include histology stain quality control
and color normalization for digital imaging [95].
11.2. Classification
The distinction between classification and unmix-
ing is illustrated in Fig. 6. The middle column shows
the three possible outcomes of classification. Classi-
fication is equivalent to spectral segmentation; it is
an exclusive operation in which a pixel or object is
assigned to a single class. In this case one could use
blue and red as the classes, and outcomes A or B might
occur depending on whether the central purple region
was more blue-like or red-like. Alternatively, 3 classes
(red, blue and purple) could be used for classifica-
tion, giving the result shown in outcome C. One might
use this technique to segment nucleus from cytoplasm,
since in theory, pixels in an image should belong to
one or the other class (ignoring for the moment the
problem of spatial overlap in thick samples). Unmix-
ing, on the other hand, determines the abundance of
blue and red at every pixel, and yields two separate
images containing the blue signal and the red signal, in
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Fig. 7. Spectral classification of subcellular compartments in immature blood cells.
this case with uniform intensities regardless of whether
the two signals spatially overlap (purple region) or
not.
For classification, simple similarity metrics, such
as Euclidean distance, can be used to compare the
spectrum at each pixel with the set of classification
spectra in the library, and then each pixel is assigned
the class it most resembles. In Fig. 7, a pair of imma-
ture dog white blood cells were vitally stained with a
single fluorescent dye, astrazone orange, and imaged
using an LCTF-based instrument. Spectral classifica-
tion tools (in this case, principal component analysis)
could distinguish cytoplasmic and nuclear compart-
ments from each other and moreover, distinguish the
two types of cells (which represented different stages
in white blood cell maturation). Examination of rep-
resentative spectra from these 4 regions shows how
subtle the spectral differences actually were. In this
case, the spectra were combinations of the astrazone
orange and fairly prominent cellular autofluorescence,
which varied in the different cellular compartments.
The actual classification spectra used in the clas-
sification procedure can either be derived from the
scene being analyzed or they can come from previously
stored data. Alternatively, unsupervised or spatially
constrained clustering methods can be used to explore
and analyze multispectral images. These are complex
solutions to difficult problems, typically found in the
remote sensing field, and will not be further discussed.
They may be, in fact, less useful than simple supervised
techniques that can be applied to more predictable cel-
lular or histological samples.
11.3. Unmixing
Unmixing, rather than classification, is the more
common analytical tool used with multispectral
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biomedical images. Overlapping signals in individ-
ual pixels will occur, for example, when labeled
molecular targets occupy similar or closely adjacent
cellular compartments, or when fluorescent signals are
intermingled with autofluorescence. Thus, one must
“unmix” the signals, typically using a model that treats
the measured spectrum (at each pixel) as a linear mix-
ture of 2 or more spectra [73]. A common variant
relies on a constrained linear unmixing approach [16],
which requires that there be only positive amounts of
the various signals (since mathematically, it is possi-
ble to model the data using negative abundances) and
which also ensures that the sum of all the class abun-
dances reaches 100% (in other words, no allowance
is made for the presence of unknown species in the
sample). Unmixing fluorescently labeled images can
become complicated or unreliable if there are multiple
autofluorescent species, or if the fluorescent dyes are
environmentally sensitive, and thus have varying spec-
tra in different regions of a cell or tissue depending on
local conditions. Also, the presence of non-linear inter-
actions, such as energy transfer, between fluorescent
species, such as energy transfer, will also introduce
errors if the simple mixing model is being relied upon.
Linear unmixing software (as described in [96])
can unmix the data quickly and accurately. If pre-
existing measurements of the spectral properties of
each component are available and assembled into
spectral “libraries” for ready use, then the unmixing
procedure requires no further interaction and can be
accomplished in milliseconds, especially if the pro-
cess is parallelized and/or ported for computations
on graphical processing units (GPUs). Alternatively,
appropriate spectra can be extracted from more com-
plex, multiply stained samples using semi-automated
spectral exploration software [40, 97]; generating
accurate libraries normally takes just a few minutes,
and once established, can be used on additional sam-
ples without further ado—as long as the samples are
imaged on the same or similar instrument platforms.
Bright field imaging has certain advantages
over fluorescence-based approaches because typically
bright field data are converted from transmission units
(what the camera natively “sees”) to optical density
(OD) units. Conversion to OD essentially makes the
spectral data independent of typically encountered
variables such as lamp intensity and color tempera-
ture, the transmission properties of any filters in the
light path, and the spectral response of the camera. The
conversion step typically involves dividing the sample
spectral image by a corresponding blank (reference)
image acquired (usually) from a clear area on a slide;
this division effectively nulls out the effects of the vari-
ables listed above, while also helpfully flat-fielding
the images. As a consequence, previously determined
spectral libraries can regularly be used and even shared
across institutions (as long as the reagents and their
intrinsic spectra remain constant). Moreover, OD val-
ues directly reflect the abundance (absorbance) of the
analytes in the specimen.
11.4. Display
After the unmixing step, the individual abundance
images generated for each of the unmixed components
can be combined into a “component” image contain-
ing all the unmixed species in one multiplane display
and manipulated like “levels” in Photoshop. Individ-
ual components can be rendered visible or invisible as
required, and can be re-colorized or otherwise adjusted
for maximum visual clarity (Fig. 8). At the same time,
the quantitative data from each of the unmixed com-
ponents is available for analysis. Such data is essential
for determining co-localization behavior, as simple
Boolean operations, or more elaborated approaches,
can be used to determine whether any pixel or anatomic
structure is simultaneously positive for two or more
markers.
When unmixing absorbing, chromogenically
labeled samples, it is possible to display the unmixed
results layered over a bright field background of just
the hematoxylin (or even H&E) signal to mimic the
appearance of conventional single-color stains. Addi-
tionally, one can re-color stains (for example, from
brown to green) to enhance legibility. Similarly, it can
be helpful to invert the color space and present the
unmixing results in “pseudo-fluorescence”; sometimes
having additive signals (in which red + green = brighter
yellow, for example) against a black background can
be a more useful viewing mode.
The converse is also true: fluorescence images
can be inverted and re-colored to resemble bright
field immunohistochemical preparations. These can be
much easier to evaluate visually, not least because spa-
tial context becomes more visible. This maneuver may
make it more likely that fluorescence-enabled tech-
niques will increasingly become part of the standard
pathology tool chest. No matter what manipulations
are used to enhance usability, it is important to recog-
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Fig. 8. Mouse bowel spectrally imaged. Four Alexa dyes and autofluorescence are unmixed; an AF-free composite is shown.
nize that these are just display options and do not affect
the underlying quantitative data.
12. Bar-coding (combinatorial labeling)
Bar-coding, if technically feasible, offers up oppor-
tunities to resolve much greater sample complexity,
and combines unmixing (to de-code the fluorescent
label signal) followed by classification via look-up
table. Barcoding works for samples that do not gen-
erally have different physical targets overlapping one
another (unless the overlap can be depth-resolved
optically, as with confocal microscopy), as it may
otherwise be impossible to unambiguously assign a
classification to areas of an image with mixed bar-
code signals. One of the first major applications of
spectral imaging using this approach was spectral kary-
otyping (SKY) [98]. With over 900 citations in the 16
years since first published in 1996, SKY revolution-
ized mouse and human cytogenetics, and SKY probes
have also been generated and applied to karyotyping
non-human primates, rats and other species. SKY used
combinatorial labeling of five fluorescent dyes (plus
a DAPI counterstain for chromosome banding) and a
simple on-off binary coding of chromosomes (i.e., On-
off-off-off-off for chromosome 1, off-on-on-on-on for
chromosome 24 (Y)) since the goal was to reach 24
human chromosomes with high confidence. The spatial
constraint is that the method required cytogenetic chro-
mosome spreads, ideally with no chromosome lying on
top of another.
The Brainbow mouse [99] and its offshoots (so
far, Drosophila, C. elegans, and Arabidopsis) have
taken combinatorial labeling into the intact organism.
By combining tissue/temporally inducible Cre recom-
binase, multiplex recombination sites encompassing
multiple fluorescent protein gene cassettes, and spec-
tral confocal microscopy, the inventors of the Brainbow
mice report that by color and intensity over 90 differ-
ent neuronal clones could be distinguished. Brainbow
techniques could be further extended with additional
colors, subcellular localization marking, fluorescent-
protein-based Fucci cell cycle indicators [100], or
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fluorescent protein biosensors, to increase information
content per cell further.
Phenotyping of complex bacterial communities rep-
resents another intriguing application of bar-coding.
In a proof of principle, Valm et al. employing
RNA FISH and combinatorial labels were able to
demonstrate 28 different binary combinations of eight
fluorophores in visualizing E. coli in a model system
[101]. Subsequently, they were able to image 15 taxa
simultaneously in naturally occurring human dental
plaque.
13. How many labels can be used
simultaneously?
The answer to this, of course, is: it depends. The
limits of conventional fluorescence-based multiplex-
ing have not yet been fully explored, and will reflect
the availability and quality of appropriate labels and
ligands. Some of the factors that affect the degree of
multiplexing that can be achieved, include the optics of
the excitation and emission paths (one filter cube set or
many?), the spectral properties and stability of the fluo-
rophores, the brightness of the sample (dye brightness,
amplification techniques, abundance of the targets,
etc.), dynamic range, quantum efficiency and noise
properties of the sensor, and the amount of confound-
ing autofluorescence, and so on. A big factor affecting
the degree of multiplexing possible is which general
labeling technique is used—immunohistochemistry
(perhaps 4 to 5) versus immunofluorescence (∼10),
for example.
A lack of suitable labeling techniques that can be
readily employed without extensive in-house R& D has
been an obstacle that has slowed down the adoption of
spectral imaging. Traditional primary-secondary anti-
body tandem labeling techniques can be challenging
to extend beyond 2 or 3 labels due to the diffi-
culty of avoiding interference or cross-talk between
the reagents, although a number of useful strate-
gies have been developed to overcome these [102].
The development of advanced immunological labeling
reagents (e.g., Zenon Technology from Life Technolo-
gies) allows the simultaneous use of several primary
antibodies from the same species (e.g., mouse, rabbit,
etc.) [103]. Multi-color plus multi-intensity multiplex-
ing has also been documented using Zenon technology
in the flow-cytometer [104].
Nevertheless, much detailed optimization is typi-
cally needed for each new set of reagents or targets,
since fixation protocol, the order of antibody labeling,
choice of labels, amplification systems, appropriate
blocking, antibody dilution, antigen retrieval steps and
so on can all affect the utility of staining results. Ide-
ally, multiplexing should not interfere with sensitivity,
specificity or quantitative relationships between anti-
gens but it can happen that one antibody or chromogen
label may physically block the subsequent labeling of
the next antigen due to steric hindrance. In addition,
attempting to combine various labels may run into
problems of chemically incompatibility (e.g., trying
to use both water- and alcohol-soluble chromogens).
Finally, the use of multiple labels on a single spec-
imen increases the demands for appropriate controls
[105]. Fortunately, the advent of automated staining
systems can relieve some of the logistical effort, at
least, involved in multiplexed staining.
Some labeling strategies can facilitate multiplex-
ing. For example, having available primary antibodies
directly labeled with a variety of typical fluorescent
dyes provides for simple protocols, but does not over-
come the need for multiple excitation wavelengths to
cover the spectral gamut. In the last few years, the
situation has changed with the commercialization of
quantum dot labels that can be used either with antibod-
ies or molecular probes. Quantum dots are desirable in
that a whole spectral variety of quantum dot labels,
from the blue to the near-infrared, can be excited by a
single source in the UV and deep blue, making for a
simple optical set up [38, 106, 107]. Since the larger
(i.e., redder) quantum dots are typically proportion-
ately brighter than their smaller, bluer, versions, it can
be important, as in most multiplexing situations, to
ensure that the least abundant targets are tagged with
the brightest labels, to intensity-balance the resulting
signals as much as possible.
Some drawbacks of QDs continue to hinder their
adoption. These include: a propensity to aggregate;
blinking [108] (an attribute that can actually be used
to enhance their detectability [109, 110]); and justifi-
able concerns about toxicity [111, 112], at least for the
cadmium-selenium variety. Moreover, samples labeled
with quantum dots in vivo and then processed for rou-
tine histology generally lose the quantum dot fluores-
cence. This effect was recently shown to be due to metal
contaminants in most formaldehyde preparations, and
with suitable care, QD introduced in vivo can still be
detectable on subsequent histological sections [113].
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Fig. 9. Breast duct chromogenically stained for ER and PR, spectrally imaged in bright field and signals unmixed.
Recently a new class of multispectral dyes with cer-
tain advantages over quantum dots has been described
[39]. These dyes are readily synthesized on conven-
tional DNA synthesis machines and can be directly
attached via “click”-chemistry to targeting moieties
such as antibodies. Desirable properties include: very
small size (∼1 nm); lack of toxic elements such as
cadmium; and, like quantum dots, the capability of
multispectral family members to be excited at one,
near-UV wavelength region but to emit anywhere from
blue to far-red.
In the case of bright field imaging, multiple chro-
mogens of course exist for immunohistochemical
staining. Fortunately, the common combination of
DAB (brown), Fast Red (or the equivalent) for the
molecular stains, and hematoxylin as the counterstain
actually is quite well suited for spectral unmixing
(Fig. 9). Getting past two or three chromogenic stains
can be a challenge, but certain combinations of chro-
mogens have been identified as being suitable for
multiplexed spectral detection [102], and new chro-
mogen combinations are being developed with this
application specifically in mind. This will greatly
enhance the use of simultaneous molecular stains for
research and clinical pathology. While IHC-reagent
suppliers have begun to develop multi-color IHC
antibody- and chromogen panels (such as those, for
example, available from BioCare Medical), their kits
have largely employed labeling strategies that target
different colors to non-spatially overlapping tissue ele-
ments (to avoid problems of color mixing that can make
visual or standard digital color-based analyses diffi-
cult). If such companies develop application-specific
kits that could take advantage of improved bright field
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Fig. 10. Spectral imaging of fluorescent in-vivo molecular staining for HER2, H&E staining of FFPE tumor tissue, multispectral imaging, and
color-space remapping.
signal separation, the usefulness and thus the use of
spectral imaging in pathology would increase.
14. Going for 100-plex: alternatives to spectral
imaging
Even with the advent of robust spectral image acqui-
sition and analysis tools, spectral overlap can set
upper limits on accuracy and dynamic range, and
as the degree of multiplexing increases, so do the
difficulties. The analogous situation in flow cytome-
try is illustrative. Flow cytometry has incrementally
moved from one to as many as 18 fluorophores,
plus forward and side scatter parameters. With just
a few fluorophores in an assay, cross-talk compensa-
tion is readily achievable, but the modern (10+)-plex
flow cytometer requires elaborate instrumentation,
computer-controlled compensation and careful assay
design [114].
A way to finesse the multiplexing problem is
to do the labeling serially, rather than simultane-
ously. Serial staining, imaging, and “erasing” protocols
can provide almost arbitrary degrees of multiplex-
ing, although they can be slow and labor-intensive.
Schubert and colleagues have achieved 50-plex and
more by using just two colors, by staining, destain-
ing (actually, photobleaching), and restaining through
multiple cycles [115–117]. Using a related approach,
Hennig and colleagues employed single-stranded
DNA-conjugated antibodies, hybridizing with fluores-
cent oligonucleotides, then destaining using adjacent
quencher oligonucleotides, and repeating, all at room
temperature [118]. Currently, both these groups use
pairs of fluorescent colors, but with spectral imaging
approaches, this could be extended to four or more per
cycle [119], increasing efficiency.
A recent publication [120] described a flow-based
method that greatly exceeded the 20-plex flow bar-
rier by switching from fluorescence to mass-encoded
mass spectrometry, using the plasma-based CyTOF
mass cytometer to measure the expression levels of
34 parameters per cell. The authors believe 60 and
perhaps even 100 parameters can be measured simulta-
neously in using this method, at the rate of 1,000 cells
per second. There are ways that this technology could
eventually be extended to the analysis of solid tissues,
although probably not with cellular-scale resolution.
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15. Some additional developments and
obstacles
The impact of whole-slide imaging in pathology
may affect the adoption of multiplexed staining and
analysis. The current models have become fast enough
to support the conversion of pathology to a largely digi-
tal discipline [121]. Multispectral imaging can readily
be adapted to at least some of these slide scanning
technologies, and preliminary work has indicates that
this combination will indeed be practical and use-
ful. Having digital information for an entire specimen
will allow for statistically valid quantitative tissue seg-
mentation and quantitation techniques operating in
a largely hands-off fashion. Pathologists would then
perform a review and validation function, along with
integration of slide imaging data with other sources
of information as part of an overall clinical assessment
[122]. As the imaging step no longer takes place on the
pathologist’s desk, it is now technically feasible to per-
form fluorescence-based staining, with its potential for
enhanced multiplexing, while delivering a bright-field-
like image to the pathologist, who ultimately may be
unaware of the manner of slide preparing and imaging
(see Fig. 10).
Quality control still remains a big barrier. It is
hard enough to maintain reproducible performance in
histopathology laboratories using conventional stain-
ing methods, especially when antibodies are involved
[123]. Molecular multiplexing will greatly increase
the need for robust sample preparation and stain-
ing protocols and equally robust use of appropriate
Fig. 11. Spectral karyotype of MDA-MB-435 single cell metaphase
with 400 chromosomes. Each chromosome is pseudocolored based
on a 5-dye spectral bar code.
positive and negative controls, both qualitative and
quantitative. Moreover, with multiple analytes, it is
hard to come up with protocols, including antigen-
retrieval steps, that will work with many protein
targets simultaneously—formaldehyde is not the per-
fect fixative.
Finally, computer-aided techniques carry the risk of
user credulity: many people operating outside of their
core expertise will accept computer-generated quanti-
tative data uncritically, especially when it is difficult
or impossible to confirm the results by eye. The use of
computerized approaches must be therefore be accom-
panied by appropriate training and skepticism [124].
16. Summary
The era of spectrally resolved microscopy is still
just beginning, with new and more affordable devices
working in both wide field and confocal modes. The
challenge has now shifted from the optical engineer-
ing phase to the development of robust and easy-to-use
acquisition, analysis and presentation software tools,
and equally importantly, the parallel development of
new and existing dyes and dye (and chromogen) com-
binations. We anticipate staining methods employing
possibly 10’s of spectrally and spatially resolvable cell
or tissue-based targets will becoming feasible in the
near future, providing information simultaneously on
the morphological, molecular and metabolic status of
cells and tissues. Spectral imaging’s ability to detect
multiple analytes in unhomogenized, spatially intact,
and possibly scanty specimens at subcellular resolution
can provide information unavailable from other molec-
ular profiling approaches such as expression arrays,
targeted or deep sequencing, serum proteomics or in-
vivo molecular imaging.
Despite the potential advantages that spectral imag-
ing has to offer over ensemble-averaged molecular
assays and conventional microscopy image capture,
it still remains confined largely to the basic science
domain and has not been widely adopted in clinical
research, much less in clinical practice. This is a pity,
since robust multiplexed imaging can provide pathol-
ogy with many of the tools needed to refine prognosis,
guide therapy selection and monitor ongoing therapeu-
tic response. One can hope that the recent advances
in multispectral hardware, software, and reagents will
lead to better understanding of disease and better care
of patients.
R. Levenson et al. / Spectral imaging in preclinical research 357
References
[1] W.A. Wells, P.E. Barker, C. MacAulay, M. Novelli, R.M.
Levenson and J.M. Crawford, Validation of novel optical
imaging technologies: The pathologists’ view, J Biomed Opt
12 (2007), 051801.
[2] M.E. van den Akker-van Marle, D. Gurwitz, S.B. Detmar,
C.M. Enzing, M.M. Hopkins, E. Gutierrez de Mesa and D.
Ibarreta, Cost-effectiveness of pharmacogenomics in clini-
cal practice: A case study of thiopurine methyltransferase
genotyping in acute lymphoblastic leukemia in Europe,Phar-
macogenomics 7 (2006), 783–792.
[3] M. Titford, The long history of hematoxylin, Biotech His-
tochem 80 (2005), 73–78.
[4] R.E. Heller, A requiem for aniline dyes, Perspect Biol Med
35 (1992), 398–400.
[5] C.R. Taylor and R.J. Cote, Immunohistochemical markers of
prognostic value in surgical pathology, Histol Histopathol 12
(1997), 1039–1055.
[6] S.S. Bacus, D.A. Altomare, L. Lyass, D.M. Chin, M.P. Far-
rell, K. Gurova, A. Gudkov and J.R. Testa, AKT2 is frequently
upregulated in HER-2/neu-positive breast cancers and may
contribute to tumor aggressiveness by enhancing cell sur-
vival, Oncogene 21 (2002), 3532–3540.
[7] R.K. Reddy, C. Mao, P. Baumeister, R.C. Austin, R.J. Kauf-
man and A.S. Lee, Endoplasmic reticulum chaperone protein
GRP78 protects cells from apoptosis induced by topoiso-
merase inhibitors: Role of ATP binding site in suppression
of caspase-7 activation, J Biol Chem 278 (2003), 20915–
20924.
[8] J. Cicenas, P. Urban, W. Kung, V. Vuaroqueaux, M. Labuhn,
E. Wight, U. Eppenberger and S. Eppenberger-Castori,
Phosphorylation of tyrosine 1248-ERBB2 measured by
chemiluminescence-linked immunoassay is an independent
predictor of poor prognosis in primary breast cancer patients,
Eur J Cancer 42 (2006), 636–645.
[9] O. David, J. Jett, H. LeBeau, G. Dy, J. Hughes, M. Friedman
and A.R. Brody, Phospho-Akt overexpression in non-small
cell lung cancer confers significant stage-independent sur-
vival disadvantage, Clin Cancer Res 10 (2004), 6865–6871.
[10] E. Tokunaga, Y. Kimura, E. Oki, N. Ueda, M. Futatsugi, K.
Mashino, M. Yamamoto, M. Ikebe, Y. Kakeji, H. Baba and Y.
Maehara, Akt is frequently activated in HER2/neu-positive
breast cancers and associated with poor prognosis among
hormone-treated patients, Int J Cancer 118 (2006), 284–289.
[11] A. Lugli, I. Zlobec, P. Minoo, K. Baker, L. Tornillo, L.
Terracciano and J.R. Jass, Role of the mitogen-activated pro-
tein kinase and phosphoinositide 3-kinase/AKT pathways
downstream molecules, phosphorylated extracellular signal-
regulated kinase, and phosphorylated AKT in colorectal
cancer-a tissue microarray-based approach, Hum Pathol 37
(2006), 1022–1031.
[12] S.B. Vestey, C. Sen, C.J. Calder, C.M. Perks, M. Pignatelli
and Z.E. Winters, Activated Akt expression in breast can-
cer: Correlation with p53, Hdm2 and patient outcome, Eur J
Cancer 41 (2005), 1017–1025.
[13] S. Yamamoto, Y. Tomita, Y. Hoshida, T. Morooka, H. Nagano,
K. Dono, K. Umeshita, M. Sakon, O. Ishikawa, H. Ohi-
gashi, S. Nakamori, M. Monden and K. Aozasa, Prognostic
significance of activated Akt expression in pancreatic ductal
adenocarcinoma, Clin Cancer Res 10 (2004), 2846–2850.
[14] J. Luo, B.D. Manning and L.C. Cantley, Targeting the
PI3K-Akt pathway in human cancer: Rationale and promise,
Cancer Cell 4 (2003), 257–262.
[15] J. Bergqvist, G. Elmberger, J. Ohd, B. Linderholm, J. Bjohle,
H. Hellborg, H. Nordgren, A.L. Borg, L. Skoog and J. Bergh,
Activated, ERK1/2 and phosphorylated oestrogen receptor
alpha are associated with improved breast cancer survival
in women treated with tamoxifen, Eur J Cancer 42 (2006),
1104–1112.
[16] R.M. Levenson, E.S. Wachman, W. Niu and D.L. Farkas,
Spectral imaging in biomedicine: A selective overview, Proc
SPIE 3438 (1998), 300–312.
[17] M.P. DiGiovanna and D.F. Stern, Activation state-specific
monoclonal antibody detects tyrosine phosphorylated
p185neu/erbB-2 in a subset of human breast tumors over-
expressing this receptor, Cancer Res 55 (1995), 1946–1955.
[18] B.Z. Ring, R.S. Seitz, R. Beck, W.J. Shasteen, S.M. Tarr, M.C.
Cheang, B.J. Yoder, G.T. Budd, T.O. Nielsen, D.G. Hicks,
N.C. Estopinal and D.T. Ross, Novel prognostic immuno-
histochemical biomarker panel for estrogen receptor-positive
breast cancer, J Clin Oncol 24 (2006), 3039–3047.
[19] D. Loussouarn, J. Brunon, H. Avet-Loiseau, M. Campone
and J.F. Mosnier, Prognostic value of HER2 expression in
meningiomas: An immunohistochemical and fluorescence in
situ hybridization study, Hum Pathol 37 (2006), 415–421.
[20] S.M. Wiseman, N. Makretsov, T.O. Nielsen, B. Gilks, E.
Yorida, M. Cheang, D. Turbin, K. Gelmon and D.G. Hunts-
man, Coexpression of the type 1 growth factor receptor family
members HER-1, HER-2, and HER-3 has a synergistic neg-
ative prognostic effect on breast carcinoma survival, Cancer
103 (2005), 1770–1777.
[21] G. Jayaram and E.M. Elsayed, Cytologic evaluation of prog-
nostic markers in breast carcinoma, Acta Cytol 49 (2005),
605–610.
[22] N.A. Makretsov, D.G. Huntsman, T.O. Nielsen, E. Yorida,
M. Peacock, M.C.U. Cheang, S.E. Dunn, M. Hayes, M. van
de Rijn, C. Bajdik and C.B. Gilks, Hierarchical clustering
analysis of tissue microarray immunostaining data identifies
prognostically significant groups of breast carcinoma, Clin
Cancer Res 10 (2004), 6143–6151.
[23] S. Abdul-Rasool, S.H. Kidson, E. Panieri, D. Dent, K. Pillay
and G.S. Hanekom, An evaluation of molecular markers for
improved detection of breast cancer metastases in sentinel
nodes, J Clin Pathol 59 (2006), 289–297.
[24] W. Pao and N. Girard, New driver mutations in non-small-cell
lung cancer, The Lancet Oncology 12 (2011), 175–180.
[25] P.T. Nelson, D.A. Baldwin, W.P. Kloosterman, S. Kauppinen,
R.H. Plasterk and Z. Mourelatos, RAKE and LNA-ISH reveal
microRNA expression and localization in archival human
brain, RNA 12 (2006), 187–191.
[26] P.T. Nelson, M. De Planell-Saguer, S. Lamprinaki, M. Kiri-
akidou, P. Zhang, U. O’Doherty and Z. Mourelatos, A
novel monoclonal antibody against human Argonaute pro-
teins reveals unexpected characteristics of miRNAs in human
blood cells, RNA 13 (2007), 1787–1792.
[27] S.S. Jeffrey, Cancer biomarker profiling with microRNAs,
Nat Biotechnol 26 (2008), 400–401.
358 R. Levenson et al. / Spectral imaging in preclinical research
[28] N.L. Simone, R.F. Bonner, J.W. Gillespie, M.R. Emmert-
Buck and L.A. Liotta, Laser-capture microdissection:
Opening the microscopic frontier to molecular analysis,
Trends Genet 14 (1998), 272–276.
[29] J.M. Lubieniecka and T.O., Nielsen, cDNA microarray-based
translational research in soft tissue sarcoma, Journal of Sur-
gical Oncology 92 (2005), 267–271.
[30] R.E. Banks, M.J. Dunn, M.A. Forbes, A. Stanley, D. Pappin,
T. Naven, M. Gough, P. Harnden and P.J. Selby, The potential
use of laser capture microdissection to selectively obtain dis-
tinct populations of cells for proteomic analysis– preliminary
findings, Electrophoresis 20 (1999), 689–700.
[31] F. Fend, M.R. Emmert-Buck, R. Chuaqui, K. Cole, J. Lee,
L.A. Liotta and M. Raffeld, Immuno-LCM: Laser capture
microdissection of immunostained frozen sections for mRNA
analysis, Am J Pathol 154 (1999), 61–66.
[32] J. Liu, S.K. Lau, V.A. Varma, B.A. Kairdolf and S. Nie, Mul-
tiplexed detection and characterization of rare tumor cells in
Hodgkin’s lymphoma with multicolor quantum dots, Anal
Chem 82 (2010), 6237–6243.
[33] M.H. Oktay, F.B. Gertler, Y.F. Liu, T.E. Rohan, J.S. Con-
deelis and J.G. Jones, Correlated immunohistochemical and
cytological assays for the prediction of hematogenous dis-
semination of breast cancer, J Histochem Cytochem 60
(2012), 168–173.
[34] W.J. Frable, Pathologic classification of soft tissue sarcomas,
Semin Surg Oncol 10 (1994), 332–339.
[35] Z.H. Zhu, B.Y. Sun, Y. Ma, J.Y. Shao, H. Long, X. Zhang,
J.H. Fu, L.J. Zhang, X.D. Su, Q.L. Wu, P. Ling, M. Chen,
Z.M. Xie, Y. Hu and T.H. Rong, Three immunomarker sup-
port vector machines-based prognostic classifiers for stage
IB non-small-cell lung cancer, J Clin Oncol 27 (2009),
1091–1099.
[36] M.A. Rubin, M.P. Zerkowski, R.L. Camp, R. Kuefer, M.D.
Hofer, A.M. Chinnaiyan and D.L. Rimm, Quantitative
determination of expression of the prostate cancer protein
alpha-methylacyl-CoA racemase using automated quanti-
tative analysis (AQUA): A novel paradigm for automated
and continuous biomarker measurements, Am J Pathol 164
(2004), 831–840.
[37] T.J. Fountaine, S.M. Wincovitch, D.H. Geho, S.H. Garfield
and S. Pittaluga, Multispectral imaging of clinically rel-
evant cellular targets in tonsil and lymphoid tissue using
semiconductor quantum dots, Mod Pathol 19 (2006), 1181–
1191.
[38] R.J. Byers and E.R. Hitchman, Quantum dots brighten
biological imaging, Prog Histochem Cytochem 45 (2011),
201–237.
[39] J. Guo, S. Wang, N. Dai, Y.N. Teo and E.T. Kool, Multispec-
tral labeling of antibodies with polyfluorophores on a DNA
backbone and application in cellular imaging, ProcNatl Acad
Sci U S A 108 (2011), 3493–3498.
[40] J.R. Mansfield, K.W. Gossage, C.C. Hoyt and R.M. Leven-
son, Autofluorescence removal, multiplexing, and automated
analysis methods for in-vivo fluorescence imaging, J Biomed
Opt 10 (2005), 41207.
[41] R.M. Levenson and J.R. Mansfield, Multispectral imaging in
biology and medicine: Slices of life, Cytometry A 69 (2006),
748–758.
[42] B. Clancy and L.J. Cauller, Reduction of background autoflu-
orescence in brain sections following immersion in sodium
borohydride, J Neurosci Methods 83 (1998), 97–102.
[43] W. Baschong, R. Suetterlin and R.H. Laeng, Control of
autofluorescence of archival formaldehyde-fixed, paraffin-
embedded tissue in confocal laser scanning microscopy
(CLSM), J Histochem Cytochem 49 (2001), 1565–1572.
[44] T.J. Staughton, C.J. McGillicuddy and P.D. Weinberg,
Techniques for reducing the interfering effects of autoflu-
orescence in fluorescence microscopy: Improved detection
of sulphorhodamine B-labelled albumin in arterial tissue, J
Microsc 201 (2001), 70–76.
[45] M. Neumann and D. Gabel, Simple method for reduction of
autofluorescence in fluorescence microscopy, J Histochem
Cytochem 50 (2002), 437–439.
[46] P.C. Roche, V.J. Suman, R.B. Jenkins, N.E. Davidson, S. Mar-
tino, P.A. Kaufman, F.K. Addo, B. Murphy, J.N. Ingle and
E.A. Perez, Concordance between local and central labora-
tory HER2 testing in the breast intergroup trial N9831, J Natl
Cancer Inst 94 (2002), 855–857.
[47] C.R. Taylor and R.M. Levenson, Quantification of
immunohistochemistry–issues concerning methods, utility
and semiquantitative assessment II, Histopathology 49
(2006), 411–424.
[48] W.J. Cukierski and D.J. Foran, Metamerism in Multispectral
Imaging of Histopathology Specimens. Proceedings/IEEE
International SymposiumonBiomedical Imaging:Fromnano
to macro, IEEE International Symposium on Biomedical
Imaging 2010 (2010), 145–148.
[49] M. Speicher, S. Gwyn Ballard and D. Ward, Karyotyping
human chromosomes by combinatorial multi-fluor FISH, Nat
Genet 12 (1996), 368–375.
[50] J.A. Kiernan, Suppressing autofluorescence, Biotech His-
tochem 77 (2002), 232.
[51] R. Levenson, P.J. Cronin and K.P. Pankratov, Spectral imag-
ing for brightfield microscopy, Proc SPIE 4959 (2003),
27–33.
[52] R. Levenson, Putting the “more” back in morphology: Spec-
tral imaging and image analysis in the service of pathology,
Arch Pathol Lab Med 132 (2008), 748–757.
[53] S. Villette, S. Pigaglio-Deshayes, C. Vever-Bizet, P. Validire
and G. Bourg-Heckly, Ultraviolet-induced autofluorescence
characterization of normal and tumoral esophageal epithe-
lium cells with quantitation of NAD(P)H, Photochem
Photobiol Sci 5 (2006), 483–492.
[54] D. Chorvat, Jr., J. Kirchnerova, M. Cagalinec, J. Smolka,
A. Mateasik and A. Chorvatova, Spectral unmixing of flavin
autofluorescence components in cardiac myocytes, Biophys
J 89 (2005), L55–L57.
[55] A.A. Ghazaryan, P.S. Hu, S.J. Chen, H.Y. Tan and C.Y. Dong,
Spatial and temporal analysis of skin glycation by the use of
multiphoton microscopy and spectroscopy, J Dermatol Sci,
2011.
[56] B. Lin, M.S. Bergholt, D.P. Lau and Z. Huang, Diagnosis of
early stage nasopharyngeal carcinoma using ultraviolet aut-
ofluorescence excitation-emission matrix spectroscopy and
parallel factor analysis, Analyst 136 (2011), 3896–3903.
[57] R.S. DaCosta, H. Andersson, M. Cirocco, N.E. Marcon and
B.C. Wilson, Autofluorescence characterisation of isolated
R. Levenson et al. / Spectral imaging in preclinical research 359
whole crypts and primary cultured human epithelial cells
from normal, hyperplastic, and adenomatous colonic mucosa,
J Clin Pathol 58 (2005), 766–774.
[58] B.H. Li and S.S. Xie, Autofluorescence excitation-emission
matrices for diagnosis of colonic cancer, World J Gastroen-
terol 11 (2005), 3931–3934.
[59] M. Monici, G. Agati, F. Fusi, R. Pratesi, M. Paglierani, V.
Santini and P.A. Bernabei, Dependence of leukemic cell
autofluorescence patterns on the degree of differentiation,
Photochem Photobiol Sci 2 (2003), 981–987.
[60] M. Monici, V. Basile, G. Romano, L. Evangelisti, L. Lucarini,
M. Attanasio, E. Bertini, F. Fusi, G.F. Gensini, G. Pepe,
Fibroblast autofluorescence in connective tissue disorders:
A future tool for clinical and differential diagnosis? Journal
of Biomedical Optics 13 (2008), 054025.
[61] A. Del Fiore, M. Reverberi, A. Ricelli, F. Pinzari, S. Serranti,
A.A. Fabbri, G. Bonifazi and C. Fanelli, Early detection of
toxigenic fungi on maize by hyperspectral imaging analy-
sis, International Journal of Food Microbiology 144 (2010),
64–71.
[62] J.M. Lerner, N. Gat, E. Wachman, Approaches to spectral
imaging hardware, Current Protocols in Cytometry/Editorial
Board, J. Paul Robinson, managing Editor... [et al.]Chapter
12 (2010), Unit 12 20.
[63] M.E. Dickinson, G. Bearman, S. Tille, R. Lansford, S.E.
Fraser, Multi-spectral imaging and linear unmixing add
a whole new dimension to laser scanning fluorescence
microscopy, Biotechniques 31 (2001), 1272, 1274-1276,
1278.
[64] B. Rajwa, Modern confocal microscopy, Current Protocols
in Cytometry/Editorial Board, J. Paul Robinson, managing
Editor... [et al.] Chapter 12 (2005), Unit 12 3.
[65] Z. Malik, M. Dishi and Y. Garini, Fourier transform multi-
pixel spectroscopy and spectral imaging of protoporphyrin
in single melanoma cells, Photochem. Photobiol 63 (1996),
608–614.
[66] B.K. Ford, C.E. Volin, S.M. Murphy, R.M. Lynch and
M.R. Descour, Computed tomography-based spectral imag-
ing for fluorescence microscopy, Biophys J 80 (2001), 986–
993.
[67] A. Gorman, D.W. Fletcher-Holmes and A.R. Harvey, Gen-
eralization of the Lyot filter and its application to snapshot
spectral imaging, Optics express 18 (2010), 5602–5608.
[68] D.J. Mordant, I. Al-Abboud, G. Muyo, A. Gorman, A. Sal-
lam, P. Ritchie, A.R. Harvey and A.I. McNaught, Spectral
imaging of the retina, Eye 25 (2011), 309–320.
[69] A.A. Wagadarikar, N.P. Pitsianis, X. Sun and D.J. Brady,
Video rate spectral imaging using a coded aperture snapshot
spectral imager, Optics express 17 (2009), 6368–6388.
[70] C.F. Cull, K. Choi, D.J. Brady and T. Oliver, Identification
of fluorescent beads using a coded aperture snapshot spectral
imager, Applied optics 49 (2010), B59–B70.
[71] L. Gao, R.T. Kester, N. Hagen and T.S. Tkaczyk, Snapshot
Image Mapping, Spectrometer, (IMS) with high sampling
density for hyperspectral microscopy, Optics express 18
(2010), 14330–14344.
[72] C.D. Tran, Development and analytical applications of mul-
tispectral imaging techniques: An overview, Fresenius J Anal
Chem 369 (2001), 313–319.
[73] Y. Hiraoka, T. Shimi and T. Haraguchi, Multispectral imaging
fluorescence microscopy for living cells, Cell Struct Funct 27
(2002), 367–374.
[74] G. Bearman, R. Levenson, Biological Imaging Spectroscopy,
In: Biomedical Photonics Handbook, T. Vo-Dinh, Editor,
CRC Press, Boca Raton, (2003), p. 8 1-8 26.
[75] M.M. Schulz, F. Wehner and H.D. Wehner, The use of
a tunable light source (Mini-Crimescope MCS-400, SPEX
Forensics) in dissecting microscopic detection of cryptic
epithelial particles, Journal of forensic sciences 52 (2007),
879–883.
[76] Y. Garini, N. Katzir, D. Cabib, R.A. Buckwald, D.G.
Soenksen, Z. Malik, Spectral Bio-Imaging, In: Fluorescence
Imaging Spectroscopy and Microscopy, X.F. Wang and B.
Herman, Editors., John Wiley & Sons, Inc., 1996.
[77] G. Themelis, J.S. Yoo and V. Ntziachristos, Multispectral
imaging using multiple-bandpass filters, Optics letters 33
(2008), 1023–1025.
[78] R. Neher and E. Neher, Optimizing imaging parameters for
the separation of multiple labels in a fluorescence image,
Journal of Microscopy 213 (2004), 46–62.
[79] T.C. Wood, S. Thiemjarus, K.R. Koh, D.S. Elson, G.Z.
Yang, Optimal feature selection applied to multispectral
fluorescence imaging, in: Medical image computing and
computer-assisted intervention (MICCAI), London, 2008.
[80] J. Minet, J. Taboury, F. Goudail, M. Pe´alat, N. Roux, J.
Lonny and Y. Ferrec, Influence of band selection and tar-
get estimation error on the performance of the matched
filter in hyperspectral imaging, Applied Optics 50 (2011),
4276–4285.
[81] C. Hoyt, Liquid crystal tunable filters clear the way for
imaging multiprobe fluorescence,Biophotonics International
July/August (1996), 49–51.
[82] E.S. Wachman, W. Niu and D.L. Farkas, AOTF microscope
for imaging with increased speed and spectral versatility,
Biophysical Journal 73 (1997), 1215–1222.
[83] T. Huang, L.M. Browning and X.H. Xu, Far-field photostable
optical nanoscopy (PHOTON) for real-time super-resolution
single-molecular imaging of signaling pathways of single live
cells, Nanoscale, 2012.
[84] A.J. Chaudhari, S. Ahn, R. Levenson, R.D. Badawi, S.R.
Cherry and R.M. Leahy, Excitation spectroscopy in mul-
tispectral optical fluorescence tomography: Methodology,
feasibility and computer simulation studies, Physics in
Medicine and Biology 54 (2009), 4687–4704.
[85] C. Dunsby, P.M.P. Lanigan, J. McGinty, D.S. Elson, J.
Requejo-Isidro, I. Munro, N. Galletly, F. McCann, B. Tre-
anor, B. ¨Onfelt, D.M. Davis, M.A.A. Neil and P.M.W. French,
An electronically tunable ultrafast laser source applied to
fluorescence imaging and fluorescence lifetime imaging
microscopy, Journal ofPhysicsD:AppliedPhysics37 (2004),
3296.
[86] K.R. Koh, T. Wood, H. Zhang, K. Lekadir, D. Elson, G.-Z.
Yang, Fluorescence excitation spectroscopic imaging with
a tuneable light source and dimensionality reduction using
FR-IsoMap, Proc SPIE 6848 (2008), 68480Z-1-8.
[87] W.C. Chan and S. Nie, Quantum dot bioconjugates for
ultrasensitive nonisotopic detection, Science 281 (1998),
2016–2018.
360 R. Levenson et al. / Spectral imaging in preclinical research
[88] T.D. Lacoste, X. Michalet, F. Pinaud, D.S. Chemla, A.P.
Alivisatos and S. Weiss, Ultrahigh-resolution multicolor
colocalization of single fluorescent probes, Proc Natl Acad
Sci U S A 97 (2000), 9461–9466.
[89] J. Itoh and R.Y. Osamura, Quantum dots for multicolor tumor
pathology and multispectral imaging, Methods Mol Biol 374
(2007), 29–42.
[90] M.J. Booth, A. Jesacher, R. Juskaitis and T. Wilson, Full
spectrum filterless fluorescence microscopy, Journal of
microscopy 237 (2010), 103–109.
[91] L. Gao, N. Hagen and T.S. Tkaczyk, Quantitative comparison
between full-spectrum and filter-based imaging in hyperspec-
tral fluorescence microscopy, J Microsc, 2012.
[92] A. Mazhar, S. Dell, D.J. Cuccia, S. Gioux, A.J. Durkin, J.V.
Frangioni and B.J. Tromberg, Wavelength optimization for
rapid chromophore mapping using spatial frequency domain
imaging, Journal of Biomedical Optics 15 (2010), 061716.
[93] I.B. Styles, Selection of optimal filters for multispectral imag-
ing, Applied Optics 47 (2008), 5585–5591.
[94] Z. Shi and S. Yang, Robust high-order matched filter for
hyperspectral target detection, Electronics Letters 46 (2010),
1065–1066.
[95] Y. Yagi, Color standardization and optimization in whole
slide imaging, Diagnostic pathology 6(Suppl 1) (2011),
S15.
[96] D.L. Farkas, C. Du, G.W. Fisher, C. Lau, W. Niu, E.S. Wach-
man and R.M. Levenson, Non-invasive image acquisition
and advanced processing in optical bioimaging, Comput Med
Imaging Graph 22 (1998), 89–102.
[97] H. Xu and B.W. Rice, In-vivo fluorescence imaging with a
multivariate curve resolution spectral unmixing technique,
Journal of Biomedical Optics 14 (2009), 064011.
[98] E. Schrock, S. du Manoir, T. Veldman, B. Schoell, J. Wien-
berg, M.A. Ferguson-Smith, Y. Ning, D.H. Ledbetter, I.
Bar-Am, D. Soenksen, Y. Garini and T. Ried, Multicolor
spectral karyotyping of human chromosomes, Science 273
(1996), 494–497.
[99] J. Livet, T.A. Weissman, H. Kang, R.W. Draft, J. Lu, R.A.
Bennis, J.R. Sanes and J.W. Lichtman, Transgenic strategies
for combinatorial expression of fluorescent proteins in the
nervous system, Nature 450 (2007), 56–62.
[100] M. Sugiyama, A. Sakaue-Sawano, T. Iimura, K. Fukami,
T. Kitaguchi, K. Kawakami, H. Okamoto, S. Higashijima
and A. Miyawaki, Illuminating cell-cycle progression in the
developing zebrafish embryo, Proceedings of the National
Academy of Sciences of the United States of America 106
(2009), 20812–20817.
[101] A.M. Valm, J.L. Mark Welch, C.W. Rieken, Y. Hasegawa,
M.L. Sogin, R. Oldenbourg, F.E. Dewhirst and G.G. Borisy,
Systems-level analysis of microbial community organization
through combinatorial labeling and spectral imaging, Pro-
ceedings of the National Academy of Sciences of the United
States of America 108 (2011), 4152–4157.
[102] C.M. van der Loos, Multiple immunoenzyme staining: Meth-
ods and visualizations for the observation with spectral
imaging, J Histochem Cytochem 56 (2008), 313–328.
[103] X. Tang, J. He, J. Partin, A. Vafai, Comparative analysis
of direct fluorescence, Zenon labeling, and quantum dot
nanocrystal technology in immunofluorescence staining,
Journal of immunoassay & immunochemistry 31 (2010),
250–257.
[104] J.A. Bradford, G. Buller, M. Suter, M. Ignatius, J.M.
Beechem, Fluorescence-intensity multiplexing: Simultane-
ous seven-marker, two-color immunophenotyping using flow
cytometry,CytometryPartA:The Journal of the International
Society for Analytical Cytology 61 (2004), 142–152.
[105] M.K. Szeszel, C.L. Crisman, L. Crow, S. McMullen, J.M.
Major, L. Natarajan, A. Saquib, J.R. Feramisco and L.M.
Wasserman, Quantifying estrogen and progesterone receptor
expression in breast cancer by digital imaging, J Histochem
Cytochem 53 (2005), 753–762.
[106] S.J. Rosenthal, J.C. Chang, O. Kovtun, J.R. McBride, I.D.
Tomlinson, Biocompatible quantum dots for biological appli-
cations, Chemistry & biology 18 (2011), 10–24.
[107] E. Tholouli, J.A. Hoyland, D. Di Vizio, F. O’Connell, S.A.
Macdermott, D. Twomey, R. Levenson, J.A. Yin, T.R. Golub,
M. Loda and R. Byers, Imaging of multiple mRNA targets
using quantum dot based in situ hybridization and spec-
tral deconvolution in clinical biopsies, Biochem Biophys Res
Commun 348 (2006), 628–636.
[108] B. Bruhn, J. Valenta, F. Sangghaleh and J. Linnros, Blinking
statistics of silicon quantum dots, Nano letters 11 (2011),
5574–5580.
[109] X. Shi, Z. Xie, Y. Song, Y. Tan, E.S. Yeung and H. Gai,
Superlocalization spectral imaging microscopy of a multi-
color quantum dot complex, Analytical chemistry 84 (2012),
1504–1509.
[110] P. Hoyer, T. Staudt, J. Engelhardt and S.W. Hell, Quantum dot
blueing and blinking enables fluorescence nanoscopy, Nano
letters 11 (2011), 245–250.
[111] M. Bottrill and M. Green, Some aspects of quantum dot
toxicity, Chemical communications 47 (2011), 7039–7050.
[112] W. Liu, S. Zhang, L. Wang, C. Qu, C. Zhang, L. Hong, L.
Yuan, Z. Huang, Z. Wang, S. Liu, G. Jiang, CdSe quantum dot
(QD)-induced morphological and functional impairments to
liver in mice, PloS one 6 (2011), e24406.
[113] D. Zarkowsky, L. Lamoreaux, P. Chattopadhyay, R.A. Koup,
S.P. Perfetto, M. Roederer, Heavy metal contaminants can
eliminate quantum dot fluorescence, Cytometry Part A: The
Journal of the International Society for Analytical Cytology
79 (2011), 84–89.
[114] I.P. Sugar, J. Gonzalez-Lergier and S.C. Sealfon, Improved
compensation in flow cytometry by multivariable optimiza-
tion, Cytometry A 79 (2011), 356–360.
[115] Sequential analysis of biological samples, US, Editor, 2009.
[116] S. Pierre and K. Scholich, Toponomics: Studying protein-
protein interactions and protein networks in intact tissue, Mol
Biosyst 6 (2010), 641–647.
[117] W. Schubert, A. Gieseler, A. Krusche, P. Serocka and R.
Hillert, Next-generation biomarkers based on 100-parameter
functional super-resolution microscopy TIS, N Biotechnol,
2011.
[118] C. Hennig, N. Adams, G. Hansen, A versatile platform for
comprehensive chip-based explorative cytometry, Cytometry
Part A: The Journal of the International Society forAnalytical
Cytology 75 (2009), 362–370.
[119] E. Barash, S. Dinn, C. Sevinsky and F. Ginty, Multiplexed
analysis of proteins in tissue using multispectral fluores-
R. Levenson et al. / Spectral imaging in preclinical research 361
cence imaging, IEEE Trans Med Imaging 29 (2010), 1457–
1462.
[120] S.C. Bendall, E.F. Simonds, P. Qiu, A.D. Amir el, P.O.
Krutzik, R. Finck, R.V. Bruggner, R. Melamed, A. Trejo,
O.I. Ornatsky, R.S. Balderas, S.K. Plevritis, K. Sachs, D.
Pe’er, S.D. Tanner and G.P. Nolan, Single-cell mass cytome-
try of differential immune and drug responses across a human
hematopoietic continuum, Science 332 (2011), 687–696.
[121] R.S. Weinstein, The S-curve framework: Predicting the future
of anatomic pathology, Arch Pathol Lab Med 132 (2008),
739–742.
[122] B.A. Friedman, A survey of the myriad forces changing
anatomic pathology and their consequences, Arch Pathol Lab
Med 132, 735-738.
[123] V.K. Anagnostou, A.W. Welsh, J.M. Giltnane, S. Siddiqui,
C. Liceaga, M. Gustavson, K.N. Syrigos, J.L. Reiter and
D.L. Rimm, Analytic variability in immunohistochemistry
biomarker studies, Cancer Epidemiol Biomarkers Prev 19
(2010), 982–991.
[124] A.J. North, Seeing is believing? A beginners’ guide to prac-
tical pitfalls in image acquisition, J Cell Biol 172 (2006),
9–18.
